Key facts
- Dartsbio Pharmaceuticals’s last known valuation is $15.7M (May 2020).
- It has raised $36.0M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Guangdong Yuecai Venture Capital, Fuho Capital, Zhongshan Xiwan Investment Holding Development, Guangdong Gaowei Investment Management, Jingxing Tiancheng (Ningbo) Private Equity Fund Management — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Dartsbio Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Dartsbio Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dartsbio Pharmaceuticals
Developer of antibody drugs intended to improve the quality of life for cancer patients. The company offers antibody discovery, antibody molecular engineering, and new-generation antibody humanization and develops monoclonal antibody drugs, bispecific antibody drugs, and antibody conjugate drugs (ADC), enabling patients to cure cancer without morphine addiction and tolerance.
- Sector
- Healthcare
- HQ
- Zhongshan, China
- Founded
- 2017
- Employees
- 21
- Website
- dartsbio.com/
- Ownership
- Privately Held (backing)
Dartsbio Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dartsbio Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dartsbio Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.